Amgen's Biosimilar IP Win Was Wrong, Hospira Tells Fed. Circ.
Law360 (December 11, 2018, 8:52 PM EST) -- Hospira has urged the Federal Circuit to toss a $70 million jury verdict finding its biosimilar version of Amgen Inc.’s blockbuster anemia treatment Epogen infringed an Amgen patent, arguing its drug production was protected by a safe harbor for companies seeking federal approval for biosimilar products.
In Monday’s 66-page opening brief, Hospira urged the appellate court to toss a Delaware jury’s verdict finding that it infringed Amgen’s patent that covers the creation of specialized erythropoietin protein cells, or EPO, that stimulate the creation of red blood cells in anemia patients. The jury found that only seven of the 21 drug batches created...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!